Insights

  • Date

  • Content Type

  • Reset

Article

Scientific Due Diligence: The Force Behind Biopharma Merger and Acquisition Success.

16.06.22

By Diane Seimetz & Jörg Schneider

Partnering, mergers and acquisitions (M&As), and product licensing require careful planning, particularly…..
Read More

Article

The future of CMC for novel therapies

10.06.22

By Elena Meurer

Novel and advanced therapies have come on in leaps and bounds over the past decade.
Read More

Article

Building successful partnerships with scientific due diligence

16.05.22

By Diane Seimetz & Jörg Schneider

How you can ensure a smooth and successful business partnership
Read More

Article

The how, why and when of comparability exercises for ATMPs

16.05.22

By Elena Trude

Process changes are an inevitable part of most drug development programs, and this is particularly
Read More

Article

Addressing the unique regulatory challenges of gene therapies

11.04.22

By Francesco Lanucara

Gene therapies have the potential to transform the treatment of disease by correcting an underlying
Read More

Article

Overcoming challenges for personalized cancer vaccines

11.04.22

By Ilona Baraniak and Aleksandra Nevmerzhitskaya

Advances in the field of personalized cancer vaccines create potential for more targeted, less toxic
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more